<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 20, 2020 (HealthDay News) — Preexposure prophylaxis (PrEP) is well tolerated by men who have sex with men (MSM) at episodic risk for HIV while on vacation, according to a study published online Aug. 15 in the Journal of Acquired Immune Deficiency Syndrome<\/i>.<\/p>\n
James E. Egan, Ph.D., from the University of Pittsburgh, and colleagues evaluated the feasibility of short-term, fixed-interval episodic PrEP (Epi-PrEP) for use among 48 vacationing MSM with three-month follow-up data.<\/p>\n
The researchers found that the majority (93.7 percent) had tenofovir concentrations consistent with daily use upon returning from vacation. Three-quarters reported condomless sex during vacation, while one-third reported recreational drug use. During follow-up, one participant became HIV-infected because of a lapse in continued access to PrEP after the study. No adverse events were serious. The majority of participants (70 percent) indicated an interest in daily ongoing PrEP use.<\/p>\n
“Many participants felt the experience of initiating PrEP while on vacation could be a means for transition to long-term PrEP use,” the authors write.<\/p>\n
One author disclosed financial ties to Gilead Sciences, which provided study medication.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n